Ambra BioScience LLC, founded in 2014, is a pioneering company in the Biopharma, Health Care, Life Sciences, and Medical Devices industries, headquartered in the United States. The company leverages its proprietary Gut Sensory Modulation (GSM) technology to create dietary supplements and medical foods targeting key health issues like weight management and blood sugar regulation.
By focusing on hormone release induced by nutrient-activated taste receptors in the lower gut, Ambra BioScience innovatively uses a special mix of food ingredients, or tastants, to augment the beneficial release of hormones that influence hunger, satiety, and mood. These tastants are GRAS, non-stimulatory, and non-nutritive.
With over $20 million invested in GSM's development and IP, their flagship product, Lovidia® Hunger Control Formula, is ready for broader market penetration. As of December 2017, the company secured $1.05M in a venture round and now seeks partners for technology advancement and distribution of Lovidia.